Saturday, October 30, 2010

3/4ths Of Market To Vertex's Telaprevir®: Leerink Swann & Co.

Well, this is all sort of like reading the opening night notices, on a new musical, in Boston this morning -- but here goes: Winner? Telaprevir®, per BusinessWeek:

. . . .Telaprevir will capture about three-fourths of the demand for the new medicines, said Howard Liang, an analyst at Leerink Swann & Co. in Boston, in a telephone interview. The drug, which Vertex is developing with New Brunswick, New Jersey-based Johnson & Johnson, will generate about $2.6 billion annually by 2013, he said. . . .

No comments: